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Abstract
Purpose Chemotherapy/radiotherapy-induced nausea and
vomiting (CINV/RINV) can affect half of oncology patients,
significantly impacting daily life. Nausea without vomiting has
only recently been thought of as a condition in its own right. As
such, the incidence of nausea is often underestimated. This
survey investigated the incidence and impact of CINV/RINV
in patients compared with estimations of physicians/oncology
nurses to determine if there is a perceptual gap between
healthcare professionals and patients.
Methods An online research survey of physicians, oncology
nurses and patients was conducted across five European coun-
tries. Participants had to have experience prescribing/
recommending or have received anti-emetic medication for
CINV/RINV treatment. Questionnaires assessed the incidence
and impact of CINV/RINV, anti-emetic usage and compli-
ance, and attribute importance of anti-emetic medication.
Results A total of 947 (375 physicians, 186 oncology nurses
and 386 patients) participated in this survey. The incidence of
nausea was greater than vomiting: 60 % of patients reported
nausea alone, whereas 18 % reported vomiting. Physicians
and oncology nurses overestimated the incidence of CINV/
RINV but underestimated its impact on patients’ daily lives.
Only 38 % of patients reported full compliance with physi-
cians’/oncology nurses’ guidelines when self-administering
anti-emetic medication. Leading factors for poor compliance
included reluctance to add to a pill burden and fear that
swallowing itself would induce nausea/vomiting.
Conclusions There is a perceptual gap between healthcare
professionals and patients in terms of the incidence and impact
of CINV/RINV. This may lead to sub-optimal prescription of
anti-emetics and therefore management of CINV/RINV.
Minimising the pill burden and eliminating the requirement
to swallow medication could improve poor patient compli-
ance with anti-emetic regimens.
Keywords Chemotherapy/radiotherapy-induced nausea and
vomiting . Anti-emetic . Incidence . Impact . Perceptual gap
Introduction
Nausea and vomiting induced by treatment are estimated, on
any 1 day in routine practice, to affect 35–50 % of patients
undergoing chemotherapy and/or radiotherapy [1]. One study
found that this had a significant impact on quality of life in
approximately 40% of patients affected [2, 3]. Several studies
have reported that the incidence of both nausea and vomiting
Electronic supplementary material The online version of this article
(doi:10.1007/s00520-015-2750-5) contains supplementary material,
which is available to authorized users.
* Bharat Amlani
bamlani@norgine.com
1 Alcura, Selborne House, Mill Lane, Alton, Hampshire GU34 2QJ,
UK
2 Catalan Institute of Oncology, Hospital Duran i Reynals, Gran Via
l’Hospitalet 199-203, L’Hospitalet de Llobregat,
08908 Barcelona, Spain
3 Azienda Ospedaliera San Gerado, Via Pergolesi, 33,
20900 Monza, Italy
4 University Hospital Halle (Saale), Ernst-Grube-Str. 30, 06097 Halle
(Saale), Germany
5 Norgine Ltd, Norgine House, Widewater Place, Moorhall Road,
Uxbridge UB9 6NS, UK
6 Medical Oncology and Supportive Care Cancer Unit, Hôpital
Européen Georges-Pompidou, 20 Rue Leblanc, 750175 Paris, France
Support Care Cancer (2015) 23:3297–3305
DOI 10.1007/s00520-015-2750-5
is higher 2–5 days following chemotherapy/radiotherapy (the
delayed phase) than it is during the first 24 h (the acute phase)
[4, 5]. Although significant progress has been made in the
prevention and control of chemotherapy/radiotherapy-
induced nausea and vomiting (CINV/RINV) [6], a recent
cross-sectional study in general hospitals revealed that the
incidence of acute and delayed-phase vomiting was 12 and
23 % and nausea was 39 and 68 %, respectively [7].
In patients where the risk of nausea and vomiting (emesis)
is regarded as high (highly emetogenic chemotherapy [HEC])
(>90 %) or moderate (moderately emetogenic chemotherapy
[MEC]) (30–90 %), clinical research suggests that the optimal
treatment to prevent CINV/RINV should associate a cortico-
steroid with a selective 5-HT3 receptor antagonist [8–12].
Dexamethasone is strongly recommended with a 5-HT3 an-
tagonist (palonosetron or ondansetron) and an Nk1 receptor
antagonist in high emetogenic chemotherapy regimens. Treat-
ment should be administered at least 30 min prior to initiation
of chemotherapy or radiotherapy and should continue
throughout the delayed phase. However, many patients do
not adhere to their regimen. Chan et al. [13] reported that
42 % of breast cancer patients are non-adherent to their post-
chemotherapy anti-emetic treatment. Patients may also feel
regular self-administration of anti-emetics unnecessary when
not experiencing symptoms and may then find it difficult to
gain control once symptoms present.
Nausea is reported more frequently by patients than emesis
[5, 14]. However, nausea is a subjective experience and, un-
like vomiting, difficult to define and quantify [15]. Nausea is
often not regarded by patients and carers as a condition in
itself but more frequently thought of as either a precursor or
after-effect of vomiting [16]. It is now accepted that nausea is
a distinct phenomenon, with its own mechanism of action,
grades of severity and approach to treatment [16].
Several studies have highlighted how physicians and on-
cology nurses often underestimate the extent to which patients
suffer from delayed CINV/RINV [5, 17–19]. These discrep-
ancies can cause sub-optimal adherence by physicians to cur-
rent CINV/RINV international guidelines when making pre-
scribing decisions around the use of anti-emetics [20–23]. In
addition, some patients can be reluctant to report symptoms of
CINV/RINV, having the belief that these are part of the treat-
ment process that they must endure. One study observed that
approximately one third of patients expressed the desire ‘to be
strong by not complaining’ and another that patients fear that
complaints may lead to changes in their specific cancer ther-
apy, impacting the chances of a cure [24, 25]. The differences
observed in attitudes and experience of nausea and vomiting
by physicians, nurses and patients suggest that there is a per-
ceptual gap in the incidence and impact of CINV/RINV. Thus,
it is likely that a significant proportion of patients suffer the
consequences of CINV/RINV unnecessarily, impacting sur-
vival benefit and quality of life. This may be compounded
by a lack of adherence of patients to their prescribed anti-
emetic regimens, with two thirds of oncology patients keen
to limit the amount of medication that they take [24].
We developed and utilised an observational, multinational,
online survey in order to investigate the perceptions of CINV/
RINV and understand what drives the use of anti-emetics.
Oncology physicians, oncology nurses and patients in five
European countries were surveyed to assess the impact of
CINV/RINV on patients’ lives and gain an insight into their
anti-emetic usage and satisfaction.
Methods
Participants
Inclusion criteria for physicians and nurses specialised in on-
cology were that they had been qualified for 3–35 years and
were responsible for anti-emetic prescribing decisions/
recommendations in cases of CINV/RINV (to a minimum of
20 and 10 patients per month for CINV prevention and CINV
treatment, respectively). Physicians and nurses were verified
as fully qualified and practising within their designated oncol-
ogy role. Inclusion criteria for patients with cancer (irrespec-
tive of tumour type or disease stage) were that they were aged
18 years or over and had received chemotherapy and/or radio-
therapy within the previous 24 months and had received anti-
emetics for the treatment or prevention of CINV/RINV.
Participants were sourced from those already registered
with patient and healthcare professionals’ survey panels
and were invited to take part via email. Some physicians
and oncology nurses were invited via telephone and pa-
tients via their doctor. Respondents were recruited in five
European countries (France, Germany, Italy, Spain and the
UK). Ethical and legal considerations of this survey are
described in Online Resource 1.
Questionnaire design and outcomes
Initial wording for questions and multiple-answer options for
this cross-sectional multinational survey were developed by
the authors, including a representative of the study sponsor.
The questionnaire was piloted and adapted in the UK; five
patients, two physicians and one oncology nurse completed
the questionnaire and were subsequently interviewed for feed-
back, which was used to refine the wording of the question-
naire. Questionnaires were translated into the languages of the
four other European countries for participants’ understanding.
Copies of the final questionnaires are presented in Online
Resources 2 and 3.
The questionnaire included consent and assessment of eli-
gibility and was divided into eight sections with the following
outcomes: eligibility, attitude and use of anti-emetic
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medications for CINV/RINV, incidence of CINV/RINV, im-
pact of CINV/RINVon patient quality of life, compliance with
anti-emetic regimens, patient assessment and communication,
attribute importance, and demographics and classification.
Respondents selected predefined answers, responded to
open-ended questions or rated statements based on their opin-
ions using a Likert scale [26]. Questionnaires were distributed
9 June–8 August 2014, inclusive.
Statistical analysis
Sample size was based on feasibility and was considered suf-
ficient to demonstrate statistical significance at the aggregated
country level by maintaining an error variance of below
±10%. Descriptive summary statistics, including mean values
and percentages, were used to summarise the data. Data from
respondents in the different countries were pooled to analyse
findings across the European population. Patient-physician
and patient-oncology nurse discussions in the UK were com-
pared with the rest of the European countries using 95 %
confidence intervals. The Student’s t test was used to test for




The survey population comprised 947 respondents. A total of
386 patients were enrolled: 79 from Italy, 78 from the UK, 77
from France and 76 each from Germany and Spain. In total,
375 oncologists were enrolled, 75 from each European coun-
try surveyed, and 186 oncology nurses, 40 each from Germa-
ny, Italy and Spain, 35 from France and 31 from the UK.
Incidence and impact of nausea and vomiting
Of the total number of patients, 60 % (233/386) reported
experiencing nausea only, 4 % (17/386) experienced vomiting
only following their most recent cycle of cancer therapy and
14 % (55/386) of patients reported experiencing nausea in
combination with vomiting. Therefore, nausea was reported
by 74 % of patients and vomiting by a total of 18 %. The
incidence of nausea and vomiting was higher in the acute
phase than in the delayed phase: 55 and 15 % of patients
reported acute-phase nausea or vomiting, respectively; 37
and 6 % reported delayed-phase nausea and vomiting, respec-
tively (Table 1). Physicians and oncology nurses estimated the
incidence of nausea and vomiting to be higher than patients
recalled following their last round of chemotherapy and/or
radiotherapy (Table 1). In addition, physicians and oncology
nurses’ estimates of the incidence of nausea and vomiting in
the acute phase were similar to their estimates of incidence in
the delayed phase, despite patients recalling an improvement
of symptoms in the delayed phase (Table 1).
Patients perceived the impact of nausea on their daily lives
to be similar to the impact of vomiting. Mean impact scores
(where 1 was minor impact and 10 was major impact) for
chemotherapy-induced nausea and chemotherapy-induced
vomiting were 4.6 and 5.3 in mild cases and 6.7 and 6.8 in
moderate cases, respectively. Mean impact scores for
radiotherapy-induced nausea and radiotherapy-induced
vomiting were 5.2 and 5.7 for mild cases and 6.8 and 7.0 for
moderate cases, respectively (Fig. 1). Physicians and oncolo-
gy nurses’ perceptions of the impact of CINV/RINVon daily
life were lower than reported by patients. This difference
achieved statistical significance for mild and moderate-
intensity CINV/RINV (p<0.05), with the exception of physi-
cians’ estimates of the impact of moderate chemotherapy-
induced vomiting (p=0.07). There was no statistical signifi-
cance in the difference between physicians and oncology
nurses’ perceptions and impact scores reported by patients
for severe CINV/RINV (p>0.05). Overall, 107/386 (28 %)
patients felt that oncologists underestimated the impact of
CINV/RINV. Most patients (260/386 [67 %]) responded ‘nei-
ther’ when asked if they felt that their doctor underestimated
or overestimated the impact of nausea and vomiting on their
daily lives. Few patients felt that oncologists overestimated
the impact of CINV/RINV (19/386 [5 %]).
Control of nausea and vomiting
Approximately three quarters of physicians (285/375 [76 %])
prescribed guideline-suggested prophylaxis for HEC where the
emetogenic potential of chemotherapy was high. This de-
creased to 56/375 (15 %) when emetogenic potential was mod-
erate (MEC). Most physicians (322/375 [86 %]) prescribed no
or minimal anti-emetic medication for low emetogenic chemo-
therapy (LEC) treatment. One quarter (94/375 [25 %]) of phy-
sicians reported poor side effects/tolerability and 66/375 (18%)
reported cost as being key factors making them reluctant to
prescribe prophylactic anti-emetic medication where therapy
has significant emetogenic potential.
Physicians, oncology nurses and patients were asked to rank
in order the importance of seven treatment goals when deciding
upon anti-emetic medication to reduce CINV/RINV using a
Likert scale where 1 was most desirable and 7 the least
(Table 2). Physicians and oncology nurses both ranked reducing
episodes of vomiting as more important than reducing episodes
of nausea (mean values, physicians 2.4 versus 2.9; oncology
nurses 2.6 versus 3.0, respectively). Patients’ prioritisation was
similar for reducing episodes of vomiting and reducing episodes
of nausea (mean values, 3.4 and 3.3, respectively).
Half the patients surveyed (197/386 [51 %]) were given
anti-emetic medication on the day of treatment at the hospital
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for the treatment of acute CINV/RINV; 58/197 (29%) of these
received treatment less than 30 min prior to chemotherapy/
radiotherapy. Of the total number of patients, 329/386
(85 %) were given anti-emetic medication for treatment of
delayed CINV/RINV at home. The most common form of
administration was oral: a pill/tablet (182/329 [55 %]), an
orodispersable film (73/329 [22 %]) or syrup (44/329
[13 %]). Of the 45/386 (12 %) patients that were not given
medication at home, 13/45 (29 %) were told that it was be-
cause they were unlikely to experience CINV/RINV and 14/
45 (31 %) did not know why.
Visual inspection of the data showed that in the UK,
oncology nurses had a greater role in discussing CINV/
RINV with patients than in all other European countries
surveyed and that more patients discussed this with their
oncology nurse: 22/78 (28 %), UK, compared with 19/76
Table 1 The percentage of patients’ recall and physicians and oncology nurses’ estimates of the percentage of the incidence of CINV/RINV in the
acute and delayed phases













Nausea 55 69 71 37 66 71
Vomiting 15 57 59 6 56 58

















Nausea during/following chemotherapy Nausea during/following radiotherapy















































Chemotherapy-induced nausea Radiotherapy-induced nausea
Patients vs Mild Moderate Severe Mild Moderate Severe
Physicians <0.001 <0.001 0.26 <0.001 <0.001 0.14
Oncology nurses <0.001 <0.001 0.67 <0.001 <0.001 0.89
p-values
Chemotherapy-induced nausea Radiotherapy-induced nausea
Patients vs Mild Moderate Severe Mild Moderate Severe
Physicians <0.001 0.07 0.82 <0.001 <0.001 0.25
Oncology nurses <0.001 0.04 0.38 <0.001 <0.001 0.05
Physicians Oncology nurses Patients
Fig. 1 Mean rating of the impact that nausea/vomiting has on patients’
daily lives. Data presented are mean ratings on a scale of 1 to 10, where 1
is minor impact and 10 is major impact (physicians, n=375; oncology
nurses, n=186; patients, n=386). In mild and moderate settings, the mean
score differences between physicians and oncology nurses’ and patients’
perceptions are statistically significant, with the exception of physicians’
estimates of the impact of moderate-chemotherapy-induced vomiting.
There was no statistically significant difference between physicians and
oncology nurses’ estimates of the impact of severe chemotherapy/
radiotherapy-induced nausea and vomiting compared with patients’
perceptions. p values were calculated using Student’s t test
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(25 %), Spain, 16/77 (21 %), France, 15/76 (20 %),
Germany, and 14/79 (18 %), Italy. Forty-six of 78 (59 %)
patients in the UK reported discussing CINV/RINV with
their physician whereas patient–physician discussions
were more frequent than in other European countries: 55/
79 (70 %), Italy, 54/77 (70 %), France, 50/76 (66 %), Ger-
many, and 50/76 (66 %), Spain. However, analysis of 95 %
confidence intervals demonstrated that there was no statis-
tically significant difference in patient–physician and pa-
tient–oncology nurse discussions in the UK compared with
the other European countries tested.
Similar proportions of all physicians, oncology nurses and
patients surveyed (275/375 [73 %], 124/186 [67 %] and 263/
386 [68 %], respectively) rated the interaction between patient
and care team as highly or moderately structured. The remain-
ing respondents felt that it was either loosely structured or
non-existent (Fig. 2). Furthermore, 100/375 (27%) physicians
and 61/186 (33 %) oncology nurses stated that there was no
patient assessment during the 5-day period following chemo-
therapy/radiotherapy, which was confirmed by half of the pa-
tients (Fig. 3). The main reason for not reporting CINV/RINV
was assigned to acceptance and belief that it had to be toler-
ated; this option was selected by 196/386 (51%) patients. This
was estimated by 224/375 (60 %) physicians and 139/186
(75 %) nurses to be the main reason for not reporting
CINV/RINV.
Investigations into satisfaction with anti-emetic regi-
mens revealed that 80/386 (21 %) patients considered
the anti-emetics prescribed to them on their first cycle of
chemotherapy/radiotherapy to be insufficient; a mean of
2.4 changes to medication was necessary to control nau-
sea and vomiting. Physicians estimated that the most fre-
quently administered anti-emetics were dexamethasone
(mean estimate of 59 % of patients), ondansetron
(47 %), metoclopramide (35 %) and aprepitant (25 %).
Nine per cent (36/386) of patients felt their current anti-
emetic medication to be insufficient and described them-
selves as dissatisfied.
Patient adherence with anti-emetic regimen
Physicians and oncology nurses estimated that approximately
two thirds of patients (61 and 66 %, respectively) adhered
fully to their prescribed anti-emetic regimen at home. Howev-
er, only 145/386 (38 %) patients recalled always taking their
anti-emetic medication according to their physicians’ or on-
cology nurses’ instructions (frequency/timing of self-adminis-
tration). The reason selected by most physicians (155/375
[41 %]), oncology nurses (105/186 [56 %]) and patients (67/
241 [28 %]) for poor adherence was ‘not accepting the need to
take medication until actually feeling sick’. In addition, phy-
sicians, oncology nurses and patients rated the reluctance to
add to an overall pill burden and a fear that the action of
swallowing itself would induce nausea/vomiting as discour-
aging factors when taking anti-emetic medication (Table 3).
Discussion
This survey investigated the incidence and impact of CINV/
RINV and explored differences in opinions and management
between physicians’, oncology nurses’ and patients’ experi-
ence, through an online questionnaire. Key findings included
that patients reported the incidence of nausea as being greater
than vomiting and that the impact that nausea has on patients’
daily lives is as severe as vomiting. This survey also demon-
strated that there is a perceptual gap between physicians and
oncology nurses and patients: physicians and nurses
overest imated the incidence of CINV/RINV but
underestimated the impact that this had on patients’ daily
lives.
Previous studies showed that the overall incidence of
chemotherapy/radiotherapy-induced nausea is more frequent
than vomiting, as demonstrated in the current study [5, 14,
27]. Unlike previous data [4, 5], data generated in this study
indicated that the incidence of acute CINV/RINV was greater
than delayed CINV/RINV. This could be attributed to the fact
Table 2 Mean (SD) importance of goals when deciding upon anti-emetic medication for the prevention of CINV/RINV
Treatment goals Physicians N=375 Oncology nurses N=186 Patients N=386
Reducing episodes of emesis 2.4 (1.68) 2.6 (1.52) 3.4 (1.98)
Reducing episodes of nausea 2.9 (1.58) 3.0 (1.55) 3.3 (1.88)
Improving ability of patients to continue normal daily life 3.2 (1.61) 2.7 (1.58) 3.3 (1.96)
Avoiding missed and/or delayed cycles of therapy 3.8 (1.78) 3.9 (1.74) 4.0 (1.93)
Avoiding need for patient to have to swallow pills/tablets/water when feeling sick 5.1 (1.53) 4.9 (1.63) 4.9 (1.94)
Reducing likelihood of health care professional intervention 5.4 (1.62) 5.8 (1.60) 4.4 (1.83)
Reducing overall burden of medication 5.4 (1.56) 5.1 (1.58) 4.6 (1.88)
Data presented are mean rank order on a scale of 1 to 7, where 1 is most desirable and 7 is least desirable. Note that slightly altered wording was used for
all seven goals in patient questionnaires
SD standard deviation, CINV/RINV chemotherapy/radiotherapy-induced nausea and vomiting
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that these previous studies refer specifically to patients’ first
cycle of chemotherapy, whereas this study refers to patients’
most recent cycle of treatment. As such, an element of antic-
ipatory emesis, which is a learned, psychological response that
develops following exposure to repeated chemotherapy cy-
cles, may have been incorporated [28]. Patients in this survey
recalled that nausea and vomiting both improved during the
delayed phase; however, physicians and oncology nurses
overestimated the incidence, suggesting that they might have
had preconceptions that the severity of acute CINV/RINVwas
sustained for the duration of the delayed phase. Patients whose
CINV/RINV worsened in the delayed phase have reported
that physicians did not titrate their medication to accommo-
date this, indicative of the difficulty of physicians to distin-
guish between the acute and delayed phases [7].
The patient experience can be exacerbated because of the
negative impact of CINV/RINVon daily life and its effects on
performing everyday tasks such as eating, sleeping and
socialising [29]. Patients from this survey as well as from a
previous study ranked the impact of nausea as being equally as
severe as vomiting [30], which may partly be explained by
patients often having difficulty describing nausea as it is a
subjective symptom and not a quantifiable symptom like
vomiting [29]. In addition, vomiting subsides once the patient
has been sick, whereas there is little that can be done to ease
nausea other than avoid its triggers [15]. This can be problem-
atic as triggers include food and aromas, which are difficult to
avoid [29].
When emetogenic potential of therapy was scored as high,
the majority of physicians prescribed guideline-suggested pro-
phylaxis for HEC. This decreased with emetogenic potential,
and most physicians prescribed either minimum or no anti-
emetic medication for LEC. This is likely to be compounded
by the fact that a quarter of physicians were reluctant to pre-
scribe anti-emetic medication because of their side effects.
Thus, there is the potential for anti-emetic medications to be
under-prescribed to patients whose cancer treatment is
regarded as LEC or MEC.
Current guidelines state that antiemetic prevention should
consist of a 5-HT3 receptor antagonist (such as palonosetron
or ondansetron) in combination with dexamethasone for the
treatment of acute CINV/RINV, with dexamethasone admin-
istration sustained for the duration of the delayed phase for
MEC treatment. Combination should be supplemented with
aprepitant throughout both phases for HEC treatment [10–12].















Highly structured – regular, scheduled 
contact between the patient and care team
Moderately structured – contact agreed but 
not necessarily regular or scheduled
Loosely structured – potentially no contact but 
an agreed communication channel and process
Unstructured – no scheduled 
contact. Patient contacts the care 
team if they encounter any issues
Fig. 2 Type of interaction
between patients and care team
during the 5-day period post-
administration of chemotherapy/
radiotherapy. Data are presented
as the percentage of physicians
(n=375), oncology nurses (n=
186) and patients (n=386) who
rated the interaction between the
patient and care team as highly
structured, moderately structured,


















Yes – routinely for all
Yes – but only for patients receiving 
highly emetogenic therapy
Yes – but only for patients of particular 
concern, regardless of emetogenic potential
Yes – other
Fig. 3 Assessment of patients during the 5-day period post-
administration of chemotherapy/radiotherapy. Data are presented as the
percentage of physicians (n=375) and oncology nurses (n=186) who
selected predefined answers that best described the assessment of their
patients. Patient data (n=386) are presented as the percentage of patients
contacted by their care team in the 5 days immediately following admin-
istration of chemotherapy/radiotherapy
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CINV/RINV, but no medication is required for delayed
CINV/RINV, following LEC therapy [11]. Nearly one third
of patients receiving anti-emetic medication on the day of their
treatment received it less than the 30 min prior to starting
chemotherapy/radiotherapy contrary to recommendation in
treatment guidelines [10–12]. Guideline-consistent CINV pro-
phylaxis significantly improves CINV symptoms compared
with guideline-inconsistent CINV prophylaxis [20, 23] indi-
cating that anti-emetic treatments should be administered pro-
phylactically to inhibit the initiation of nausea and vomiting.
However, as data generated by this survey applied specifically
to the patients’ most recent cycle of treatment, it may not
necessarily have reflected management throughout multiple
treatment cycles.
Physicians, oncology nurses and patients rated the structure
of the interaction between the patient and the care team sim-
ilarly following chemotherapy/radiotherapy. However, there
appeared to be inter-country variation in the responsibility
for discussing CINV/RINV with patients; in the UK, more
patients discussed CINV/RINV with their oncology nurse,
whereas in the other European countries surveyed, they did
more so with their physicians, although this trend was not
statistically significant. This may reflect the different roles of
oncology nurses in the UK compared with other European
countries; in the UK, nurses are often responsible for provid-
ing treatment and taking patient calls when they become un-
well. In the rest of Europe, however, many patients are man-
aged primarily by their physician.
Nearly two thirds of patients recalled not fully adhering to
their anti-emetic medication. As results in this study were
based on patient recall, actual adherence levels may be lower
due to incorrect self-administration [31]. The main reasons
selected for non-adherence were refusing to take medication
until actually feeling sick and the perceived inevitability of
CINV/RINV, suggesting that the majority of patients were
unaware of the relationship between anti-emetic adherence
and reduced incidence of CINV [23]. This highlights the im-
portance of reassuring patients that they should take their anti-
emetic treatment prophylactically rather than after the emer-
gence of symptoms. Anti-emetic medication in the form of a
pill/tablet was the most frequent formulation given to patients
for the treatment of delayed CINV/RINV, but the reluctance to
add to a pill burden and a fear that swallowing a pill/tablet will
itself induce nausea and/or vomiting also contributed to poor
adherence. Consequently, eliminating the requirement for
swallowing a pill/tablet would be a desirable characteristic
of anti-emetic medication and could aid poor patient adher-
ence with anti-emetic regimens.
Several potential sources of bias were identified in the
study design, which was enhanced to attenuate these. Selec-
tion bias was likely to impact our data: This was an online
survey, and so, physicians, oncology nurses and, more nota-
bly, patients who have access to the Internet may not be fully
representative of their entire demographic groups, especially
elderly patients. To mitigate this, respondents were not sub-
jected to an age limit, and patients were eligible regardless of
their tumour type and disease stage in an attempt to target as
wide a range of respondents as possible. Voluntary re-
sponse bias may also have been a factor: Recipients were
self-selected volunteers, and so, this bias may have led to
over-representation of individuals with particularly strong
opinions. We considered the whole patient population
without stratification according to class of emetic potential
regimen (high, moderate or low). Stratification would have
led to smaller numbers of patients, making analyses less
robust. Patients’ intention to please may have influenced
our results, but this risk was minimised by respondents
remaining anonymous so as not to damage the physician/
patient relationship. The desire to be ‘strong by not
complaining’ has been reported by patients in regard to
CINV/RINV [24], and this should be considered when
assessing the patient experience.
Table 3 Physicians and
oncology nurses’ estimates of the
percentage of patients influenced
by factors and patients’ ratings of
factors contributing to poor











Are reluctant to add to their overall
medication/pill burden
27.4 26.9 5.4
Fear that the action of swallowing
the pills/tables will itself induce
nausea and/or vomiting
21.3 25.1 4.8
Fear that the action of swallowing
the water needed to wash down
the pills/tablets will itself induce
nausea and/or vomiting
20.4 24.4 4.7
Dislike the unpleasant taste of the medication 14.6 14.9 4.5
Data presented for physicians and oncology nurses are mean estimates of the percentage of patients that do not
adhere to their anti-emetic regimen for the given reason. Data presented for patients is the mean rating that a factor
discourages them from using anti-emetic medication on a scale of 1–10, where 1 is not at all and 10 is strongly
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In conclusion, this study showed that there was a percep-
tual gap between the healthcare professionals (physicians and
oncology nurses) who make anti-emetic prescribing
decisions/recommendations and the patients who receive
anti-emetic treatment in terms of CINV/RINV impact on their
daily life. The severity and impact of nausea (without
vomiting) on patients were greater than physicians and oncol-
ogy nurses estimated. Physicians and nurses failed to distin-
guish between acute and delayed CINV/RINV, which could
lead to poormanagement of delayed CINV/RINV. Physicians’
adherence to clinical guidelines when prescribing anti-emetic
medication and targeting CINV/RINV prophylactically rather
than retrospectively will improve CINV/RINV. Finally, the
formulation of anti-emetic medication is important;
minimising the pill burden and eliminating the requirement
to swallow medication will improve patient adherence during
treatment for CINV/RINV.
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